Trial
NCT01253642
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
OHSU Knight Cancer Institute
Collaborators
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation
Condition
Hormone-Resistant Prostate Cancer
Intervention
Biopsy of Prostate
Why stopped
low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-02